104 related articles for article (PubMed ID: 7832989)
1. Intrinsic activity of human immunodeficiency virus type 1 protease heterologous fusion proteins in mammalian cells.
Arrigo SJ; Haines JK; Huffman KM
DNA Cell Biol; 1995 Jan; 14(1):15-23. PubMed ID: 7832989
[TBL] [Abstract][Full Text] [Related]
2. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
Wu X; Liu H; Xiao H; Kappes JC
Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
[TBL] [Abstract][Full Text] [Related]
3. Comparison of HIV-1 protease expression in different fusion forms.
Wan M; Takagi M; Loh BN; Imanaka T
Biochem Mol Biol Int; 1995 Jun; 36(2):411-9. PubMed ID: 7663445
[TBL] [Abstract][Full Text] [Related]
4. Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.
Misumi S; Morikawa Y; Tomonaga M; Ohkuma K; Takamune N; Shoji S
J Biochem; 2004 Mar; 135(3):447-53. PubMed ID: 15113844
[TBL] [Abstract][Full Text] [Related]
5. Human immunodeficiency virus-1 tat- and tat/nef-defective genomes containing HIV-regulated diphtheria toxin A chain gene inhibit HIV replication.
Brdar B; Matulić M; Rubelj I; Ivanković M; Reich E
Croat Med J; 2002 Oct; 43(5):591-7. PubMed ID: 12402403
[TBL] [Abstract][Full Text] [Related]
6. Effect of HIV constructs containing protease-reverse transcriptase fusion proteins on viral replication.
Cherry E; Morin N; Wainberg MA
AIDS; 1998 Jun; 12(9):967-75. PubMed ID: 9662192
[TBL] [Abstract][Full Text] [Related]
7. Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins.
Cherry E; Liang C; Rong L; Quan Y; Inouye P; Li X; Morin N; Kotler M; Wainberg MA
J Mol Biol; 1998 Nov; 284(1):43-56. PubMed ID: 9811541
[TBL] [Abstract][Full Text] [Related]
8. The tat gene and protein of the human immunodeficiency virus type 1.
Caputo A; Grossi MP; Rossi C; Campioni D; Balboni PG; Corallini A; Barbanti-Brodano G
New Microbiol; 1995 Jan; 18(1):87-110. PubMed ID: 7760763
[No Abstract] [Full Text] [Related]
9. Specific cleavage sites of Nef proteins from human immunodeficiency virus types 1 and 2 for the viral proteases.
Schorr J; Kellner R; Fackler O; Freund J; Konvalinka J; Kienzle N; Kräusslich HG; Mueller-Lantzsch N; Kalbitzer HR
J Virol; 1996 Dec; 70(12):9051-4. PubMed ID: 8971042
[TBL] [Abstract][Full Text] [Related]
10. Expression and purification of active form of HIV-1 protease from E.coli.
Wan M; Loh BN
Biochem Mol Biol Int; 1995 Apr; 35(4):899-912. PubMed ID: 7627139
[TBL] [Abstract][Full Text] [Related]
11. Cleavage of recombinant and cell derived human immunodeficiency virus 1 (HIV-1) Nef protein by HIV-1 protease.
Gaedigk-Nitschko K; Schön A; Wachinger G; Erfle V; Kohleisen B
FEBS Lett; 1995 Jan; 357(3):275-8. PubMed ID: 7835426
[TBL] [Abstract][Full Text] [Related]
12. In vitro binding and phosphorylation of human immunodeficiency virus type 1 Nef protein by serine/threonine protein kinase.
Bodéus M; Marie-Cardine A; Bougeret C; Ramos-Morales F; Benarous R
J Gen Virol; 1995 Jun; 76 ( Pt 6)():1337-44. PubMed ID: 7540194
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase.
Welker R; Kottler H; Kalbitzer HR; Kräusslich HG
Virology; 1996 May; 219(1):228-36. PubMed ID: 8623533
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease.
Davis DA; Brown CA; Singer KE; Wang V; Kaufman J; Stahl SJ; Wingfield P; Maeda K; Harada S; Yoshimura K; Kosalaraksa P; Mitsuya H; Yarchoan R
Antiviral Res; 2006 Nov; 72(2):89-99. PubMed ID: 16687179
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a new cell line inducibly expressing HIV-1 protease for performing safe and highly sensitive screening of HIV protease inhibitors.
Fuse T; Watanabe K; Kitazato K; Kobayashi N
Microbes Infect; 2006 Jun; 8(7):1783-9. PubMed ID: 16815068
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus type 1 gag-protease fusion proteins are enzymatically active.
Kotler M; Arad G; Hughes SH
J Virol; 1992 Nov; 66(11):6781-3. PubMed ID: 1404618
[TBL] [Abstract][Full Text] [Related]
17. A possible regulation of negative factor (Nef) activity of human immunodeficiency virus type 1 by the viral protease.
Freund J; Kellner R; Konvalinka J; Wolber V; Kräusslich HG; Kalbitzer HR
Eur J Biochem; 1994 Jul; 223(2):589-93. PubMed ID: 8055930
[TBL] [Abstract][Full Text] [Related]
18. Potent inhibition of human immunodeficiency virus type 1 (HIV-1) replication by inducible expression of HIV-1 PR multimers.
Arrigo SJ; Huffman K
J Virol; 1995 Oct; 69(10):5988-94. PubMed ID: 7666503
[TBL] [Abstract][Full Text] [Related]
19. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase.
Kräusslich HG; Ochsenbauer C; Traenckner AM; Mergener K; Fäcke M; Gelderblom HR; Bosch V
Virology; 1993 Feb; 192(2):605-17. PubMed ID: 8421902
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production.
Baraz L; Friedler A; Blumenzweig I; Nussinuv O; Chen N; Steinitz M; Gilon C; Kotler M
FEBS Lett; 1998 Dec; 441(3):419-26. PubMed ID: 9891983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
